Original article—alimentary tractRelationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease
Section snippets
Patient Population
This study was conducted at 2 tertiary care centers between November 2004 and November 2006. The protocol was approved by the institutional review board at each center. All patients gave written consent. Eligible patients were adults with an established diagnosis of Crohn's disease involving the ileum, colon, or both, who were undergoing a clinically indicated ileocolonoscopy for either assessment of disease activity or for dysplasia screening after a prolonged duration of colonic disease.
Patients
A total of 180 patients were screened for potential enrollment in the study, of whom 164 met the inclusion and exclusion criteria and were enrolled. The demographic characteristics of the patients are shown in Table 1.
The mean age of the patients was 41 years and the mean duration of disease was 12 years. Fifty-nine percent of the patients were female and 16% were current smokers. The majority of patients had ileocolonic disease (Table 2). Twenty-three percent of patients were receiving
Discussion
This study evaluated the relationship between serum and fecal biomarkers and endoscopic and clinical estimates of Crohn's disease activity. The results show that select serologic and fecal biomarkers are associated positively with endoscopic estimates of Crohn's disease activity (SES-CD), and confirm previous observations of inconsistencies between clinical and endoscopic estimates of disease activity. The results also confirm the hypothesis that selected SNPs of the CRP or CRP promoter genes
References (42)
- et al.
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
Gastroenterology
(2002) - et al.
Development of a Crohn's disease activity indexNational Cooperative Crohn's Disease Study
Gastroenterology
(1976) - et al.
Clinical, biological and endoscopic picture of attacks of Crohn's disease; evolution on prednisolone
Gastroenterology
(1990) - et al.
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
Gastrointest Endosc
(2006) - et al.
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
Gastrointest Endosc
(2004) - et al.
A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein
Atherosclerosis
(2005) - et al.
Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis
Atherosclerosis
(2002) - et al.
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators
Immunol Today
(1997) - et al.
Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin
Lancet
(1990) - et al.
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation
Am J Gastroenterol
(2003)
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease
Gastroenterology
A C-reactive polymorphism is associated with type 2 diabetes in Pima Indians
Mol Genet Metab
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
Gastroenterology
Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study
Gut
Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse
Gastroenterology
Review article: biological activity markers in inflammatory bowel disease
Aliment Pharmacol Ther
Human C-reactive protein: expression, structure and function
Mol Immunol
The clinical significance of serum C reactive protein levels in Crohn's disease
J Clin Gastroenterol
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index
Gut
Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management
Gut
Importance of laboratory parameters in the evaluation of Crohn's disease activity
J Clin Gastroenterol
Cited by (357)
Imaging Evaluation of Inflammatory Bowel Disease Complications
2022, Gastrointestinal Endoscopy Clinics of North AmericaTreat to target in Crohn’s disease: A practical guide for clinicians
2024, World Journal of GastroenterologyReduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission
2023, Journal of Gastrointestinal and Liver Diseases
Previously published in abstract form in Gastroenterology 2007;132(Suppl 2):A-M1101.
Supported by Celltech (now UCB Pharma) and the Mayo Foundation for Medical Education and Research.